An van Es-Johansson
Director/Board Member bei SAVARA INC.
Vermögen: 114 461 $ am 31.03.2024
Profil
An van Es-Johansson is currently serving as an Independent Director at Plus Therapeutics, Inc., Lumos Pharma Sub, Inc., Savara, Inc., Lumos Pharma, Inc., and as a Member-Supervisory Board at Agendia, Inc. He is also a Director at van Es Consulting AB.
In the past, he served as an Independent Director at BioInvent International AB and Medivir AB, and as VP & Head-EMENAR Medical Affairs at Swedish Orphan Biovitrum AB.
He was also the Chief Medical Officer & Head-Development at AlzeCure Pharma AB.
Dr. van Es-Johansson holds a doctorate degree from Erasmus University Rotterdam.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
SAVARA, INC.
0,02% | 14.12.2023 | 22 500 ( 0,02% ) | 112 050 $ | 31.03.2024 |
LUMOS PHARMA, INC.
0,01% | 01.03.2024 | 855 ( 0,01% ) | 2 411 $ | 31.03.2024 |
PLUS THERAPEUTICS, INC.
-.--% | 22.02.2024 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von An van Es-Johansson
Unternehmen | Position | Beginn |
---|---|---|
SAVARA INC. | Director/Board Member | 03.12.2019 |
PLUS THERAPEUTICS, INC. | Director/Board Member | 01.01.2020 |
LUMOS PHARMA, INC. | Director/Board Member | 13.02.2021 |
van Es Consulting AB | Director/Board Member | - |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Director/Board Member | - |
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Director/Board Member | 01.07.2019 |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Director/Board Member | 01.02.2021 |
Ehemalige bekannte Positionen von An van Es-Johansson
Unternehmen | Position | Ende |
---|---|---|
MEDIVIR AB | Director/Board Member | 05.05.2022 |
ALZECURE PHARMA AB | Chief Tech/Sci/R&D Officer | 01.03.2021 |
░░░░░░░░░ ░░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░ ░░░░░░░░░ ░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Ausbildung von An van Es-Johansson
Erasmus University Rotterdam | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 8 |
---|---|
BIOINVENT INTERNATIONAL AB | Health Technology |
MEDIVIR AB | Health Technology |
PLUS THERAPEUTICS, INC. | Health Technology |
SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
IRLAB THERAPEUTICS AB | Health Technology |
SAVARA INC. | Health Technology |
ALZECURE PHARMA AB | Health Technology |
LUMOS PHARMA, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Agendia NV
Agendia NV Medical/Nursing ServicesHealth Services Agendia NV discovers and develops products for clinical management of cancer. It operates as a commercial-stage molecular diagnostic company that focuses on the discovery, development, and commercialization of products to improve the quality of life for cancer patients. The company was founded by Rene Bernards and Laura van't Veer in 2003 and is headquartered in Amsterdam, the Netherlands. | Health Services |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | Health Technology |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Health Services |
van Es Consulting AB |